What drugs target PD-1 and LAG-3?

6+ drugs target PD-1 and LAG-3, including Nivolumab + Relatlimab.

PD-1 and LAG-3 — Drug Target

6 drugs 1 marketed 4 in Phase 3

All drugs that target PD-1 and LAG-3 — marketed and clinical-stage. Includes 6 drug classes acting on this target.

Nivolumab + Relatlimab · H. Lee Moffitt Cancer Center and Research Institute · Dual checkpoint inhibitor (PD-1 and LAG-3 inhibitor combination) · Oncology
Nivolumab and relatlimab together block two immune checkpoints (PD-1 and LAG-3) to enhance T-cell activation and anti-tumor immunity.

AK112, Gemcitabine, Cisplatin · Akeso · Bispecific antibody (PD-1/LAG-3 inhibitor) combined with chemotherapy · Oncology
AK112 is a bispecific antibody that simultaneously engages PD-1 and LAG-3 to enhance anti-tumor immune responses, while gemcitabine and cisplatin are chemotherapy agents that damage tumor DNA.
AK112, Carboplatin, Paxlitaxel · Akeso · Bispecific antibody (PD-1/LAG-3 inhibitor) + chemotherapy combination · Oncology
AK112 is a bispecific antibody that simultaneously engages PD-1 on immune cells and LAG-3 on T cells to enhance anti-tumor immunity, combined with carboplatin and paclitaxel chemotherapy for direct tumor cell killing.
TAR-210 · Janssen Research & Development, LLC · Bispecific antibody · Oncology
TAR-210 is a bispecific antibody targeting the PD-1 and LAG-3 immune checkpoint proteins.
Nivolumab-relatlimab FDC · Bristol-Myers Squibb · Dual checkpoint inhibitor (PD-1/LAG-3) · Oncology
This fixed-dose combination blocks both PD-1 and LAG-3 checkpoints on immune cells, releasing dual brakes on anti-tumor immunity.

AK112 with SCRT and CapeOX · fan li · Bispecific monoclonal antibody (PD-1/LAG-3 inhibitor) · Oncology
AK112 is a bispecific antibody that simultaneously engages PD-1 and LAG-3 to enhance anti-tumor immune responses, combined with chemotherapy (capecitabine and oxaliplatin) to treat solid tumors.